Pfizer and BioNTech Commence Phase 1/2 trial of Experimental COVID-19 Vaccine in the US

  • May 06, 2020 12:26 PM AEST
  • Team Kalkine

Two healthcare sector companies Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) revealed that the first participants in the Phase 1/2 clinical trial for the vaccine of BioNTech BNT162 to prevent coronavirus infection, have been dosed in the United States.

Gold MTF non-AMP

Moreover, this study is part of a global development program and is designed for the establishment of the safety, immunogenicity as well as the optimum dose level of four mRNA vaccine candidates which will be assessed in a single, continuous clinical study.

In Germany, the dosing of the first cohort of this developmental program was completed last week.

Pfizer also disclosed that this development program includes four vaccine candidates and each candidate indicating a different combination of mRNA format and target antigen.

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK